MA27349A1 - Composition cristalline renfermant de l'escitalopram. - Google Patents

Composition cristalline renfermant de l'escitalopram.

Info

Publication number
MA27349A1
MA27349A1 MA27512A MA27512A MA27349A1 MA 27349 A1 MA27349 A1 MA 27349A1 MA 27512 A MA27512 A MA 27512A MA 27512 A MA27512 A MA 27512A MA 27349 A1 MA27349 A1 MA 27349A1
Authority
MA
Morocco
Prior art keywords
composition containing
crystalline composition
containing escitalopram
escitalopram
crystalline
Prior art date
Application number
MA27512A
Other languages
English (en)
Inventor
Troels Volsgaard Christensen
Ken Liljegren
Michiel Onne Elema
Lene Andresen
Shashank Mahashabde
Sebastian P Assenza
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8160647&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA27349(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of MA27349A1 publication Critical patent/MA27349A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cephalosporin Compounds (AREA)
MA27512A 2001-07-31 2004-02-04 Composition cristalline renfermant de l'escitalopram. MA27349A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200101164 2001-07-31

Publications (1)

Publication Number Publication Date
MA27349A1 true MA27349A1 (fr) 2005-06-01

Family

ID=8160647

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27512A MA27349A1 (fr) 2001-07-31 2004-02-04 Composition cristalline renfermant de l'escitalopram.

Country Status (39)

Country Link
US (3) US6916941B2 (fr)
EP (2) EP1414435B1 (fr)
JP (4) JP2005525993A (fr)
KR (1) KR20040028947A (fr)
CN (2) CN1311819C (fr)
AR (1) AR034898A1 (fr)
AT (2) ATE352546T1 (fr)
AU (1) AU2002355624B2 (fr)
BG (1) BG108571A (fr)
BR (1) BR0206164A (fr)
CA (1) CA2451915C (fr)
CO (1) CO5560540A2 (fr)
CY (1) CY1106413T1 (fr)
DE (2) DE60217932T2 (fr)
DK (2) DK1414435T3 (fr)
EA (1) EA006213B1 (fr)
EG (1) EG24206A (fr)
ES (2) ES2280892T3 (fr)
HR (2) HRP20031073A2 (fr)
HU (1) HUP0401946A2 (fr)
IL (2) IL159326A0 (fr)
IS (1) IS7077A (fr)
MA (1) MA27349A1 (fr)
ME (1) MEP2108A (fr)
MX (1) MXPA04000849A (fr)
MY (1) MY126238A (fr)
NO (1) NO328346B1 (fr)
NZ (1) NZ530157A (fr)
PE (1) PE20030304A1 (fr)
PL (1) PL366995A1 (fr)
PT (2) PT1414435E (fr)
RS (1) RS8304A (fr)
SI (1) SI1414435T1 (fr)
TN (1) TNSN04021A1 (fr)
TR (1) TR200400189T2 (fr)
UA (1) UA79930C2 (fr)
UY (1) UY27404A1 (fr)
WO (1) WO2003011278A1 (fr)
ZA (1) ZA200309684B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL145615A0 (en) 1999-04-14 2002-06-30 Lundbeck & Co As H Method for the preparation of citalopram
US20030109577A1 (en) * 2000-10-27 2003-06-12 Ken Liljegren Pharmaceutical composition containing citalopram
US20030232881A1 (en) * 2000-10-27 2003-12-18 H. Lundbeck A/S Crystals of pharmaceutically acceptable salts of citalopram, methods of crystallization, and pharmaceutical compositions comprising them
ATE352546T1 (de) * 2001-07-31 2007-02-15 Lundbeck & Co As H Kristalline zusammensetzung enthaltend escitalopram
AR040970A1 (es) 2002-08-12 2005-04-27 Lundbeck & Co As H Metodo para la separacion de intermediarios que pueden ser utilizados para la preparacion de escitalopram
AU2003223105A1 (en) * 2003-03-24 2004-10-18 Hetero Drugs Limited Novel crystalline forms of (s)-citalopram oxalate
US20040265375A1 (en) * 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets
TWI339651B (en) * 2004-02-12 2011-04-01 Lundbeck & Co As H Method for the separation of intermediates which may be used for the preparation of escitalopram
US20050196453A1 (en) * 2004-03-05 2005-09-08 H. Lundbeck A/S Crystalline composition containing escitalopram
NZ549100A (en) * 2004-03-05 2010-02-26 Lundbeck & Co As H Crystalline composition containing escitalopram oxalate
US20110196032A1 (en) * 2005-05-20 2011-08-11 Ashish Gogia Pharmaceutical Dosage Form of an Antidepressant
TWI358407B (en) * 2005-06-22 2012-02-21 Lundbeck & Co As H Crystalline base of escitalopram and orodispersibl
US7834201B2 (en) 2005-06-22 2010-11-16 H. Lundbeck A/S Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
KR20070067173A (ko) * 2005-08-29 2007-06-27 테바 파마슈티컬 인더스트리즈 리미티드 이정점 입도 분포를 갖는 고체 미립자 타달라필
KR20080080094A (ko) 2005-10-14 2008-09-02 하. 룬트벡 아크티에 셀스카브 에스시탈로프람 및 부프로피온의 저용량 조합물을 이용한중추신경계 장애의 치료 방법
US20070134322A1 (en) * 2005-12-14 2007-06-14 Forest Laboratories, Inc. Modified and pulsatile release pharmaceutical formulations of escitalopram
GB0601286D0 (en) 2006-01-23 2006-03-01 Sandoz Ag Asymmetric synthesis
WO2008059514A2 (fr) * 2006-07-31 2008-05-22 Cadila Healthcare Limited Procédé de préparation d'escitalopram
US8252336B2 (en) 2006-10-20 2012-08-28 Ratiopharm Gmbh Escitalopram and solid pharmaceutical composition comprising the same
US20090048336A1 (en) * 2007-08-17 2009-02-19 Naveen Kumar Kolla Escitalopram oxalate powders
WO2009135646A2 (fr) * 2008-05-05 2009-11-12 Farmaprojects, Sa Compositions pharmaceutiques stables et procédés de préparation desdites compositions adaptés à l’échelle industrielle
EP2116231A1 (fr) 2008-05-07 2009-11-11 Hexal Ag Granulé comprenant de l'oxalate d'escitalopram
GR20080100696A (el) 2008-10-23 2010-05-13 Genepharm �.�. Φαρμακοτεχνικη μορφη με βελτιωμενη γευση του φαρμακευτικα αποδεκτου αλατος εσιταλοπραμης
ITMI20120448A1 (it) * 2012-01-30 2013-07-31 Carthesia Sas Composizione liofilizzata di escitalopram ossalato per somministrazione sublinguale
ITMI20120106A1 (it) * 2012-01-30 2013-07-31 Carthesia S A S Pastiglie liofilizzate di escitalopram ossalato per somministrazione sublinguale
WO2017020841A1 (fr) * 2015-08-03 2017-02-09 深圳信立泰药业股份有限公司 Composition pharmaceutique contenant du lcz696 et son procédé de préparation
JP2018016569A (ja) * 2016-07-26 2018-02-01 株式会社トクヤマ （１ｓ）−１−［３−（ジメチルアミノ）プロピル］−１−（４−フルオロフェニル）−１，３−ジヒドロイソベンゾフラン−５−カルボニトリル蓚酸塩の製造方法
WO2018190294A1 (fr) * 2017-04-10 2018-10-18 東和薬品株式会社 Composition médicinale comprenant de l'escitalopram
CN107441052A (zh) * 2017-06-21 2017-12-08 山东京卫制药有限公司 一种含有草酸艾司西酞普兰的片剂及其制备方法
KR102089737B1 (ko) * 2017-11-01 2020-03-16 한국화학연구원 에씨탈로프람을 함유한 미립구형 서방출 주사제 및 그의 제조방법
JP7453859B2 (ja) * 2020-06-22 2024-03-21 東和薬品株式会社 エスシタロプラム錠剤

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1143703A (fr) 1965-03-18
GB1358915A (en) 1971-09-13 1974-07-03 Merck & Co Inc Directly compressed tablet and composition therefor
GB1526331A (en) * 1976-01-14 1978-09-27 Kefalas As Phthalanes
GB8419963D0 (en) 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method
EP0223403B1 (fr) 1985-10-25 1993-08-04 Beecham Group Plc Dérivé de pipéridine, sa préparation et son utilisation comme médicament
GB8814057D0 (en) * 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
US5296507A (en) 1990-09-06 1994-03-22 H.Lundbeck A/S Treatment of cerbrovascular disorders
GB9325644D0 (en) 1993-12-15 1994-02-16 Smithkline Beecham Plc Novel formulation
US5683720A (en) 1994-10-28 1997-11-04 Fuisz Technologies Ltd. Liquiflash particles and method of making same
EP0714663A3 (fr) 1994-11-28 1997-01-15 Lilly Co Eli Potentialisation d'un médicament par un antagoniste du récepteur sérotonine 1A
AU5966196A (en) 1995-06-08 1997-01-09 Eli Lilly And Company Methods of treating cold and allergic rhinitis
JP3526581B2 (ja) 1997-07-08 2004-05-17 ハー・ルンドベック・アクティーゼルスカブ シタロプラムの製造方法
GB9714841D0 (en) 1997-07-14 1997-09-17 Smithkline Beecham Plc Treatment method
US5980941A (en) 1997-08-20 1999-11-09 Fuisz Technologies Ltd. Self-binding shearform compositions
US5869098A (en) 1997-08-20 1999-02-09 Fuisz Technologies Ltd. Fast-dissolving comestible units formed under high-speed/high-pressure conditions
US5840334A (en) 1997-08-20 1998-11-24 Fuisz Technologies Ltd. Self-binding shearform compositions
UA62985C2 (en) 1997-11-10 2004-01-15 Lunnbeck As H A method for the preparation of citalopram
CN1286687A (zh) * 1997-11-11 2001-03-07 H·隆德贝克有限公司 制备西酞普兰的方法
WO2000023431A1 (fr) 1998-10-20 2000-04-27 H. Lundbeck A/S Methode de preparation du citalopram
TWI230618B (en) * 1998-12-15 2005-04-11 Gilead Sciences Inc Pharmaceutical compositions of 9-[2-[[bis[(pivaloyloxy)methyl]phosphono]methoxy]ethyl]adenine and tablets or capsules containing the same
IL145615A0 (en) 1999-04-14 2002-06-30 Lundbeck & Co As H Method for the preparation of citalopram
ITMI991579A1 (it) 1999-06-25 2001-01-15 Lundbeck & Co As H Metodo per la preparazione di citalopram
AR021155A1 (es) 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
WO2001022941A1 (fr) * 1999-09-28 2001-04-05 H. Lundbeck A/S Composition granulee par fusion et forme posologique a liberation modifiee, preparee a partir de ladite composition
GB2357762B (en) 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
US6977306B2 (en) 2000-05-02 2005-12-20 Sumitomo Chemical Company, Limited Citalopram hydrobromide crystal and method for crystallization thereof
US20030232881A1 (en) * 2000-10-27 2003-12-18 H. Lundbeck A/S Crystals of pharmaceutically acceptable salts of citalopram, methods of crystallization, and pharmaceutical compositions comprising them
ATE352546T1 (de) * 2001-07-31 2007-02-15 Lundbeck & Co As H Kristalline zusammensetzung enthaltend escitalopram

Also Published As

Publication number Publication date
NZ530157A (en) 2007-06-29
SI1414435T1 (en) 2005-06-30
MY126238A (en) 2006-09-29
EA006213B1 (ru) 2005-10-27
US7420069B2 (en) 2008-09-02
DE60217932T2 (de) 2007-08-30
JP2012211186A (ja) 2012-11-01
CO5560540A2 (es) 2005-09-30
HRPK20080410B3 (en) 2009-09-30
CY1106413T1 (el) 2011-10-12
CA2451915C (fr) 2010-09-21
DK1522539T3 (da) 2007-05-07
BR0206164A (pt) 2003-10-28
EP1522539B1 (fr) 2007-01-24
PT1522539E (pt) 2007-03-30
JP5719811B2 (ja) 2015-05-20
ES2280892T3 (es) 2007-09-16
ATE352546T1 (de) 2007-02-15
MEP2108A (xx) 2010-02-10
HUP0401946A2 (hu) 2005-01-28
PL366995A1 (en) 2005-02-07
EP1414435A1 (fr) 2004-05-06
TR200400189T2 (tr) 2004-12-21
EP1522539A1 (fr) 2005-04-13
ZA200309684B (en) 2004-12-22
CN1660074A (zh) 2005-08-31
IS7077A (is) 2003-12-15
ATE286730T1 (de) 2005-01-15
NO328346B1 (no) 2010-02-01
BG108571A (en) 2005-02-28
DK1414435T3 (da) 2005-05-09
US20030212128A1 (en) 2003-11-13
UY27404A1 (es) 2003-02-28
EA200400243A1 (ru) 2004-06-24
CN1311819C (zh) 2007-04-25
DE60202615D1 (de) 2005-02-17
HRP20080410A2 (en) 2008-10-31
HK1070000A1 (en) 2005-06-10
US20080305164A1 (en) 2008-12-11
EP1414435B1 (fr) 2005-01-12
JP2005525993A (ja) 2005-09-02
IL159326A0 (en) 2004-06-01
JP5192568B2 (ja) 2013-05-08
CA2451915A1 (fr) 2003-02-13
NO20040380L (no) 2004-01-28
ES2233842T3 (es) 2005-06-16
MXPA04000849A (es) 2004-05-14
PT1414435E (pt) 2005-05-31
JP2011195591A (ja) 2011-10-06
TNSN04021A1 (en) 2006-06-01
US6916941B2 (en) 2005-07-12
JP4971477B2 (ja) 2012-07-11
CN1536997A (zh) 2004-10-13
HRP20031073A2 (en) 2004-04-30
AR034898A1 (es) 2004-03-24
AU2002355624B2 (en) 2006-02-02
WO2003011278A1 (fr) 2003-02-13
EG24206A (en) 2008-10-21
KR20040028947A (ko) 2004-04-03
DE60202615T2 (de) 2006-01-12
JP2010150283A (ja) 2010-07-08
US20050147674A1 (en) 2005-07-07
UA79930C2 (en) 2007-08-10
DE60217932D1 (de) 2007-03-15
PE20030304A1 (es) 2003-03-27
RS8304A (sr) 2006-12-15
IL159326A (en) 2010-05-31

Similar Documents

Publication Publication Date Title
ATE352546T1 (de) Kristalline zusammensetzung enthaltend escitalopram
BR0104326B1 (pt) ôcomposição aquosa de revestimentoö.
EP1365290A4 (fr) Composition de reserve
BR0216099B1 (pt) "conjunto de desgaste".
EP1268688A4 (fr) Compositions d'encre
ID26186A (id) Komposisi sampo
ID28694A (id) Komposisi sampo
EP1302813A4 (fr) Composition de reserve
ID29430A (id) Komposisi herbisida
MA26845A1 (fr) Forme cristalline de 4-carboxyamino-2-ethyl-1,2,3,4-
MA25527A1 (fr) Composition d'encollage.
ATE241597T1 (de) Geruchsmaskierte dimethylsulfid-zusammensetzung
DE69928862D1 (de) Zusammensetzung
DE69942892D1 (de) Gaserzeugende zusammensetzung
ZA200307102B (en) The use of enmantiomeric pure escitalopram.
MXPA03009698A (es) Vacuna multivalente que comprende un antigeno vih y un antigeno vsh y/o un antigeno vph.
TR199903132A3 (tr) Metalosan bilesiklerinin aktive edici kompozisyonu.
DE60025958D1 (de) 14,15-beta-methylen substituierte androgene
DE60017425D1 (de) Antitranspirant zusammensetzung enthaltend mikroemulsionen
NO20011664L (no) Sammensetning med höy renhet omfattende (7<alfa>, 17<alfa>)- 17-hydroksy-7-metyl-19-nor-17-pregn-5(10)-en-20-yn-3-on
ZA200006118B (en) Novel composition.
ID26295A (id) Komposisi keras-ultraviolet
ID26485A (id) Komposisi paroksetina
ZA200000192B (en) Novel composition.
ID28359A (id) Komposisi